search
Back to results

Prophylaxis for Aspiration of Gastric Contents.

Primary Purpose

Pulmonary Aspiration of Gastric Contents

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Drug either PPIS or H2RA and prokinetics
orogastric intubation
Sponsored by
King Saud University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pulmonary Aspiration of Gastric Contents focused on measuring g a, bile reflux. PPIs, H2RAs, prokinetic agents

Eligibility Criteria

15 Years - 70 Years (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: ASA I and II aged 15-70 years

-

Exclusion Criteria:

Patients with upper gastrointestinal disorders, Body mass index above 35 kg/m2, Receiving medicines known to effect the secretory and or motor functions of stomach, Had undergone surgery on stomach, With difficult intubation Intestinal obstruction, Partuients and Diabetes

.

-

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm 5

    Arm Type

    Placebo Comparator

    Active Comparator

    Active Comparator

    Active Comparator

    Other

    Arm Label

    Group C (placebo)

    Either PPIs or H2RAs

    Either PPIs or H2RAs+prokinetics

    Either PPIs or H2RAs+Prokinetic

    Intervention Orogastric intubation

    Arm Description

    Drug intervention Two doses of Placebo at 8.00 pm and then at 6.00 am Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo)

    Drug Intervention Two doses at 8.00 pm and then at 6.00 am Group L (lansoprazole 15 mg) Group E(esomeprazole 20 mg) Group P (pantoprazole 20 mg) Group R (rabeprazole 10 mg) Group O (omeprazole 20 mg) Group T (cimetidine 200 mg) Group F (famotidine 20 mg) Group N (nizatidine 150 mg) Group Z (ranitidine 150 mg) Group S (lafutidine 10 mg)

    Drug intervention Two doses at 8.00 pm and then at 6.00 am Group L D (lansoprazole 15 mg+ domperidone 10 mg) Group EM (esomeprazole 20 mg+metoclopramide 10 mg) Group PD (pantoprazole 20 mg+domperidone 10) Group RM (rabeprazole 10 mg+metoclopramide 10 mg) Group OD (omeprazole 20 mg+domperidone 10) Group TD (cimetidine 200 mg+domperidone 10) Group FM (famotidine 20 mg+metoclopramide 10 mg) Group NM (nizatidine 150 mg+metoclopramide 10 mg) Group ZD (ranitidine 150 mg+ domperidone 10 mg) Group SD (lafutidine 10 mg+domperidone 10 mg)

    Drug intervention Two doses at 8.00 pm and then at 6.00 am Group OM (omeprazole 20 mg +metoclopramide 10 mg) Group SM (lafutidine 10 mg + metoclopramide 10 mg )

    After general anesthesia, an oro-gastric tube was inserted through another endotracheal tube placed in upper esophagus into the stomach for aspiration of gastric contents.

    Outcomes

    Primary Outcome Measures

    pH of gastric contents
    pH was measured with pH meter. Unit whole digit with two decimal point for example, 4.24

    Secondary Outcome Measures

    volume of gastric contents
    Measured with graduated syringe. Units milliliters (ml)

    Full Information

    First Posted
    February 28, 2016
    Last Updated
    March 8, 2016
    Sponsor
    King Saud University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02703896
    Brief Title
    Prophylaxis for Aspiration of Gastric Contents.
    Official Title
    "Effect of Orally Administered Two Successive Doses of PPIs and/ or H2RAs Without or With a Prokinetic Drug, on the Intragastric pH and Volume and Bile Refluxate in Adults Patients Undergoing Elective Surgery.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2012 (undefined)
    Primary Completion Date
    January 2012 (Actual)
    Study Completion Date
    December 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    King Saud University

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Effect of orally administered two equal and consecutive doses of proton pump inhibitors, omeprazole, lansoprazole, esomeprazole , rabeprazole and pantoprazole and Histamine 2 receptor antagonists cimetidine, ranitidine,famotidine,nizatidine and lafutidine without and with a prokinetic agents domperidone, metoclopramide and erythromycin on intragastric pH, volume and bile refluxate.
    Detailed Description
    (This description is for one drug and similar for other drugs) We repacked the placebo, lansoprazole 15 mg and lansoprazole 15 mg plus domperidone 10 mg in 180 envelopes (times two) and then two envelope in one envelope each for evening and morning of the same size, shape and color and their name were changed as drug one, drug two and drug three by a person who was not taking part in the study to the patients (single-blind) and investigators (double-blind) blinded of it. The group assign paper was sealed in another envelope that was opened to know which drug corresponds to either drug one or drug two or drug three after the statistical analysis(triple-blind). On the preoperative anaesthesia visit, a day before surgery, the nature and purpose of the study was explained to each patient. We asked each patient to pick up on one envelop from the envelopes (randomization). Thus the patients were allocated to either Group C (control), Group L lansoprazole 15 mg or Group LD lansoprazole 15 mg with domperidone 10 mg randomly by sealed envelope method. Age, sex, ASA physical status, weight, height, BMI and the study drug given were recorded for each patient. All patients also received tablet diazepam 5 mg with study drugs. These drugs were given orally with 20 ml of drinking water at 8:00 p.m. in the evening day before surgery and 6:00 a.m. morning on the day of surgery. According to the hospital policy, all patients were fasted from 12:00 midnight. Upon arrival in the receiving area of the operating room. All patients were asked if they had been aware of any unusual feeling (side effect) after taking the study drug. In the operating room, routine monitors were attached to the patients and turned on. After pre-oxygenation with 100% O2 by face mask using eight breaths vital capacity method, anaesthesia was induced with injection fentanyl 1-2 mcg/kg, propofol 2-3 mg/kg and rocuronium 0.6-0.9 mg/kg. Lungs were ventilated taking care not to inflate the stomach. Maintaining cricoid pressure trachea was intubated with cuffed endotracheal tube. Placement and position was confirmed with EtCO2 monitor and then secured properly. After establishing stable anaesthesia, an endotracheal tube sized 8.5 internal diameter was passed via oral route in the esophagus with anterior displacement of larynx. A predetermined length marked with adhesive tape (xiphoid process to ear lobule- fro ear lobule to nasal tip) of stomach tube sized 18 F was passed through the esophageally placed endotracheal tube. Placement of this tube within the stomach was verified with auscultation over the epigastrium during insufflation of 10-15 ml of air. Gastric contents were gently aspirated manually with 60 ml syringe by an investigator who was blind of group assignment. Applying manual pressure over the epigastrium while the patient was in supine and then left and right lateral positions, gastric tube was then manipulated to ensure maximum emptying of gastric contents. The stomach tube was then removed followed by esophageally placed endotracheal tube. Any problem encountered during inserting or removing the oro-esophageally placed endotracheal tube or gastric tube was also recorded. The volume of gastric contents was measured with graduated syringe and pH using pH meter. The pH meter was calibrated using standard buffers at pH values of 4, 7 and 9.20. This pH meter has a precision of 0.01 units over the entire pH range. A minimum of one-millimeter volume of gastric contents was sufficient for pH determination with pH meter. In case of very little amount of gastric contents, we cut the stomach tube and aspirated gastric material with disposable plastic pipette. Samples less than one-millimeter were considered as no gastric contents because a minimum of one- millimeter of gastric contents was sufficient for pH- metry. Using bile salts as marker for bile, we applied qualitative Hay's sulphur test for the presence of bile salts. A minimum volume of one millimeter of gastric contents was adequate to perform Hay's sulphur test. In this test finely powered sulphur is sprinkled on the surface of cool (17 OC or below) liquid. If bile salts are present sulphur sinks down, sooner or later, in accordance with their percentage. If bile salts are present in from 1:5,000 (0.02%or 200 mcg/ml to 1:10,000 (0.01% or 100 mcg/ml) sulphur at once begins to sink and all precipitated in two or three minutes; even in dilution of 1:120,000 (0.0008% or 8.33 mcg/ml precipitation occurs. On the other hand, if sulphur remains floating on the surface, bile salts are absent. Anaesthesia was maintained with air, O2 and sevoflorane. Patients also received incremental doses of fentanyl and rocuronium as required. At the end of surgery, injection atropine and neostigmine were given to antagonize the residual effect of rocuronium. All patients were extubated in lateral position and then transferred to recovery room. Time since premedication T1 (time from evening dose till aspiration of gastric contents) and Time since premedicationT2 (time from morning dose till aspiration of gastric contents), pH, volume of gastric contents and results of Hay's sulphur test were also recorded for all patients. Statistical test were performed using GraphPad Software, Inc., San Diego, United States and results are expressed as absolute values or mean ± standard deviation SD (SEM). Statistical analysis between the groups were carried out using analysis of variance (ANOVA) for age, BMI, time since premedication T1, time since NPO and T2 , pH and volume. Chi square test was applied for sex, ASA physical status, Hay's test and risk of aspiration according to criteria defined (pH ≤ 2.5 and volume ≥ 0.4ml/kg or 25 ml. Post hoc tests with Bonferrni correction applied where p-value significant(p <0,05). A p-value of less than 0.05 was considered statistically significant. Power analysis revealed that the sample size (n= 30) in each group was of the study was sufficient to detect a difference of 0.7 among the groups in gastric pH and volume at a significant level of 0.05 (=α 0 with a power of 0.85.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pulmonary Aspiration of Gastric Contents
    Keywords
    g a, bile reflux. PPIs, H2RAs, prokinetic agents

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    1920 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Group C (placebo)
    Arm Type
    Placebo Comparator
    Arm Description
    Drug intervention Two doses of Placebo at 8.00 pm and then at 6.00 am Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo) Group C (placebo)
    Arm Title
    Either PPIs or H2RAs
    Arm Type
    Active Comparator
    Arm Description
    Drug Intervention Two doses at 8.00 pm and then at 6.00 am Group L (lansoprazole 15 mg) Group E(esomeprazole 20 mg) Group P (pantoprazole 20 mg) Group R (rabeprazole 10 mg) Group O (omeprazole 20 mg) Group T (cimetidine 200 mg) Group F (famotidine 20 mg) Group N (nizatidine 150 mg) Group Z (ranitidine 150 mg) Group S (lafutidine 10 mg)
    Arm Title
    Either PPIs or H2RAs+prokinetics
    Arm Type
    Active Comparator
    Arm Description
    Drug intervention Two doses at 8.00 pm and then at 6.00 am Group L D (lansoprazole 15 mg+ domperidone 10 mg) Group EM (esomeprazole 20 mg+metoclopramide 10 mg) Group PD (pantoprazole 20 mg+domperidone 10) Group RM (rabeprazole 10 mg+metoclopramide 10 mg) Group OD (omeprazole 20 mg+domperidone 10) Group TD (cimetidine 200 mg+domperidone 10) Group FM (famotidine 20 mg+metoclopramide 10 mg) Group NM (nizatidine 150 mg+metoclopramide 10 mg) Group ZD (ranitidine 150 mg+ domperidone 10 mg) Group SD (lafutidine 10 mg+domperidone 10 mg)
    Arm Title
    Either PPIs or H2RAs+Prokinetic
    Arm Type
    Active Comparator
    Arm Description
    Drug intervention Two doses at 8.00 pm and then at 6.00 am Group OM (omeprazole 20 mg +metoclopramide 10 mg) Group SM (lafutidine 10 mg + metoclopramide 10 mg )
    Arm Title
    Intervention Orogastric intubation
    Arm Type
    Other
    Arm Description
    After general anesthesia, an oro-gastric tube was inserted through another endotracheal tube placed in upper esophagus into the stomach for aspiration of gastric contents.
    Intervention Type
    Drug
    Intervention Name(s)
    Drug either PPIS or H2RA and prokinetics
    Other Intervention Name(s)
    Drug treatment, lansoprazole, esomeprazole,pantoprazole,rebeprazole, omeprazole,cimetidine,nizatidine,famotidine,ranitidine,lafutidine
    Intervention Description
    Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 ) Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10) Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10) Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg) Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10) Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10) Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10) Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10) Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10) Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)
    Intervention Type
    Procedure
    Intervention Name(s)
    orogastric intubation
    Other Intervention Name(s)
    OGT Insertion
    Intervention Description
    OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.
    Primary Outcome Measure Information:
    Title
    pH of gastric contents
    Description
    pH was measured with pH meter. Unit whole digit with two decimal point for example, 4.24
    Time Frame
    Immediate after induction of general anaesthesia
    Secondary Outcome Measure Information:
    Title
    volume of gastric contents
    Description
    Measured with graduated syringe. Units milliliters (ml)
    Time Frame
    Immediate after induction of general anesthesia.
    Other Pre-specified Outcome Measures:
    Title
    bile salts in the gastric contents
    Description
    Hay's Sulfur test performed on gastric contents, reported as positive or negative for bile salts
    Time Frame
    immediate after induction of general anesthesia.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    15 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: ASA I and II aged 15-70 years - Exclusion Criteria: Patients with upper gastrointestinal disorders, Body mass index above 35 kg/m2, Receiving medicines known to effect the secretory and or motor functions of stomach, Had undergone surgery on stomach, With difficult intubation Intestinal obstruction, Partuients and Diabetes . -
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    ALTAF HUSSAIN, FCPS,EDAIC
    Organizational Affiliation
    Assistant Professor and Consultant Anaesthetist
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes

    Learn more about this trial

    Prophylaxis for Aspiration of Gastric Contents.

    We'll reach out to this number within 24 hrs